Trial Profile
PRevention of cArdiac Dysfunction During Adjuvant Breast Cancer Therapy: A Randomized, Placebo-controlled, Multicenter Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2023
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms PRADAII
- 16 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 04 Aug 2021 Planned End Date changed from 1 Apr 2022 to 14 Sep 2025.
- 04 Aug 2021 Planned primary completion date changed from 1 Apr 2022 to 14 Sep 2024.